Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021

Positive results were announced by Singapore's Covid vaccine candidate ARCT-021, developed by Arcturus Therapeutics together with Duke-NUS Medical School.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.